SummaryPregnant rats, treated with high doses of propranolol, gave birth to small for dates neonates. Litter size was affected in daily doses of 100 and 150 mg/kg/day. Propranolol markedly influenced the gain in weight normally observed in pregnant rats. The placentas of the rats which received the higher doses of propranolol weighed about 30% less than normal placentas. SpeculationPregnant rats, treated with propranolol, gave birth to small for dates neonates. This effect is possibly the result of a drug-induced reduction in transport across cellular membranes, resulting in malnutrition. Since similar effects were reported in humans, treatment with propranolol during pregnancy should be further reevaluated in laboratory animals.The administration of propranolol to pregnant women is slowly gaining acceptance. If the present trend continues it will possibly become one of the more extensively used drugs for a variety of conditions associated with pregnancy such as: Lypertension (2,6), hyperthyroidism (1, 12), cardiac arrhythmias (13,16,20), and hypertrophic obstructive cardiomyopathy (5,7,25). A relatively laree number of side effects on the Drocess of ~arturition and on Y 1 1 the newborn have been reported. One of these side effects is intrauterine growth retardation (2, 6, 16) often accompanied by a small or fibrotic placenta (6, 16). These findings are thought to be caused by sustained increase in uterine muscle tone or hemodynamic changes in the mother and in the fetus resulting from Padrenoceptor blockade by propranolol(l6). In previous investigations we have shown that high concentrations of propranolol partially inhibit the uptake of amino acids (17, 18), uridine and thymidine (19), and 2-deoxyglucose (3) by chick embryo liver cells in vitro. Preliminary experiments indicate that the same inhibition may occur in mammalian cells, both in vitro and in vivo. This creates a situation analogous to starvation, which would exert its effects mainly on rapidly dividing cells or tissues with a hiah metabolic rate.Propranolol cFosses the mammalian placenta (14) and its pharmacologic effects on the fetus are easily demonstrated (9, 10). In view of our previous laboratory findings and the reports of small placentas and fetuses in women receiving propranolol during pregnancy, a methodical investigation on the effects of this drug in pregnant rats was initiated. MATERIALS AND METHODS ANIMALSThe experiments were carried out using Wistar rats, randomly bred, and weighing 140-160 g. Timed pregnant rats were obtained by mating virgin females with experienced male rats for a 24-hr period. dl-Propranolol was administered starting the morning after impregnation.Oral administration of dl-propranolol was achieved by dissolving the drug in the water imbibed by the rats. The concentrations of propranolol in the drinking water were based upon long term measurements of the average consumption of water containing propranolol per rat per 24 hr, which was found to be about 25 & 7 ml/day. The concentrations were such that each group of ra...

Control of apoptosis (apo) is very important for diagnosis, prognosis and treatment of rheumatoid arthritis (RA). Recently, we found that an appearance of specific cell surface GC is attributable to apo and developed lectin-induced agglutination test for apo evaluation. The aim of current study was to estimate changes in surface GC expression in peripheral blood lymphocytes (PBL) of normal healthy donors (NHD) and patients with RA, measured by cell agglutination with the galactose-specific VAA lectin and by lectin-cytochemical analysis. In parallel, these changes in apo incidence were evaluated by the detection of cells with sub-G1 DNA content. The data revealed an increased level of apo in lymphocytes of RA patients (n = 29), and increased cell surface GC expression in lymphocytes of NHD (n = 18). A correlation (R = 0.708) was observed between these two indicators. Specific changes in cell surface GC can be effectively used for the detection of apo cells in RA and other autoimmune disorders.

Patients with active lymphoproliferative diseases were shown to have high activity of erythrocyte uroporphyrinogen synthetase (URO‐S), the enzyme which converts porphobilinogen to uroporphyrinogen. In a few patients examined the lymphocyte URO‐S was markedly increased. No correlation was found between the high URO‐S activity and the degree of anemia, reticulocytosis, or the presence of hemolysis. Patients with epithelial malignancies and with some common viral diseases had normal erythrocyte URO‐S values. Three patients with nonalcoholic cirrhosis also had high erythrocyte URO‐S activities. The determination of erythrocyte and lymphocyte URO‐S activity may be of aid in the diagnosis of lymphoproliferative diseases. It may also indicate whether remission has been achieved and whether treatment should be continued or reinstituted. These preliminary observations justify the investigation of a larger patient and control material.

No abstract